Frank Vinluan is a Senior Biopharma Reporter for MedCity News. With a focus on the biopharmaceutical industry, Frank covers topics such as drug approvals, mergers and acquisitions, clinical trial data, and advancements in gene therapy and cell therapy. His articles provide insights into the latest developments and trends in the biopharma sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Frank Vinluan's coverage is heavily focused on the healthcare and pharmaceutical industry, with an emphasis on mergers and acquisitions, drug development, FDA approvals, and biotech. He frequently cites data in his articles, indicating a reliance on factual evidence.
Given his focus on M&A deals and drug developments within the healthcare sector, Frank may be interested in receiving pitches related to exclusive insights from industry experts or company executives involved in these transactions or new developments. Pitches emphasizing unique data-driven analyses or perspectives from key opinion leaders could also resonate well with him.
As there is no specific geographic focus mentioned for Frank's reporting, relevant news or expert analysis from any location within the global pharmaceutical and biotech industries would likely be of interest to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Frank Vinluan
Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It's the sixth FDA-approved indication for the blockbuster drug.
By: Frank Vinluan
Bristol Myers Squibb is turning to the prime-editing technology of Prime Medicines for the R&D of new cell therapies for cancer and immunology. The pharma giant is paying $110 million up front to begin the collaboration.
By: Frank Vinluan
Kailera Therapeutics licensed its portfolio of metabolic disorder drugs from Hengrui. The most advanced program has results from a Phase 2 test in China suggesting it could be competitive with other medications that target the GLP-1 and GIP receptors to trigger weight loss.
By: Frank Vinluan
Lilly Medicine Foundry will research new ways to manufacture medicines. Eli Lilly says in addition to supporting the manufacturing of drugs for clinical trials, manufacturing innovations from the site will be transferred to the company's other facilities for use in full-scale drug production.
By: Frank Vinluan
Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE. The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026.
Recordati is acquiring Sanofi's Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal's value to more than $1 billion.
By: Frank Vinluan
Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In other recent regulatory news, we have drug approvals, clinical holds, and one product withdrawal.
By: Frank Vinluan
Cardiovascular disease drugs in development intended to reduce lipoprotein (a) are mostly injectable medications, though Eli Lilly also has both oral and injectable drugs in the clinic. AstraZeneca aims to hit that key protein target with an oral small molecule licensed from CSPC Pharmaceutical Group.
By: Frank Vinluan
Astellas secured an exclusive option to license global rights to an AviadoBio gene therapy in development as a one-time treatment for a certain type of frontotemporal dementia. A Phase 1/2 test of the AviadoBio gene therapy is ongoing.
By: Frank Vinluan
On the heels of Phase 3 data showing muscle improvement in the rare neuromuscular disease spinal muscular atrophy, Scholar Rock raised $300 million in a stock offering. U.S. and European regulatory submissions for the drug are now planned for early 2025.
(833) 317-6278 
